血衍生的人类X因子缩剂,用于治疗遗传性X因子缺乏症患者
Miguel A Escobar1, Kaan Kavakli2
1University of Texas Health Science Center at Houston-McGovern Medical School and the Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, USA.
概括
血衍生X因子 (pdFX) 有效治疗和预防遗传性X因子缺乏症 (HFXD) 患者的出血. 这种治疗在HFXD患者的按需,预防和外科手术期间使用是安全的,耐受性良好.
科学领域:
- 血液学 血液学 血液学
- 罕见疾病 罕见疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 遗传性X因子缺乏症 (HFXD) 是一种罕见的自体逆向性出血障碍.
- 患有HFXD的患者面临严重出血事件的风险.
- 像PCC和FFP这样的传统治疗方法具有重大风险.
研究的目的:
- 审查HFXD患者血衍生X因子 (pdFX) 的疗效和安全性.
- 为了评估pdFX的按需治疗,预防和术后管理.
- 评估pdFX在HFXD不同严重程度的结果.
主要方法:
- 关于pdFX在HFXD中使用的五项研究 (TEN01,TEN02,TEN03,TEN05,TEN06) 的综述.
- 研究包括前性和后性设计.
- 根据血FX活性 (FX:C),患者被分为轻度,中度和严重缺乏症组.
主要成果:
- pdFX在按需出血治疗方面表现出高的成功率 (97.6%,66.6%,三个研究中的100%).
- 在两项研究中,pdFX的预防性使用在100%的患者中被评为"优秀"以预防出血.
- 发现pdFX是安全的,耐受性很好,经过术后管理和药理动力学评估.
结论:
- 审查的研究支持使用pdFX来控制HFXD的出血.
- pdFX对于按需治疗,例行预防和外科手术期间的护理是有效的.
- 血衍生X因子为HFXD患者提供了安全有效的治疗选择.
相关概念视频
01:29Venous Thrombosis III: Interprofessional Care
10
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
10
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
723
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
723
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K